Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance
about
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy AdultsImpact of physiologically based pharmacokinetic models on regulatory reviews and product labels: Frequent utilization in the field of oncologyApplication of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in JapaneseTranslational learning from clinical studies predicts drug pharmacokinetics across patient populations.A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application.Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines.Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In VitroUpdate and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.Integrating In Vitro, Modeling, and In Vivo Approaches to Investigate Warfarin Bioequivalence.Humans Vary, So Cardiac Models Should Account for That Too!Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications.Reduced order modeling and analysis of the human complement system.Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.Pharmacokinetics of Chlorin e₆-Cobalt Bis(Dicarbollide) Conjugate in Balb/c Mice with Engrafted Carcinoma.Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations.Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.Implications of inter-correlation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.Revisiting the role of gut wall in the fate of orally administered drugs: Why now and to what effect?Toxicokinetics in Risk Evaluations.Bridging the Data Gap From Toxicity Testing to Chemical Safety Assessment Through Computational Modeling
P2860
Q33571585-31086527-CF36-45A2-845C-BACEA7061D54Q33632130-207C83C7-D934-48D7-94C5-53167D52F6C6Q33703161-FBF6FE13-E6E0-4C5C-BD3D-B76BE225660EQ33767468-D052AD9C-423D-4E26-9AAF-1DB52BC4476CQ37554425-1FCAE74F-01F2-4442-9368-342EA1DEECDBQ38759413-A4E1D1E6-7CB7-481B-80BF-4C3E41FD0F91Q38774572-0BFE4729-E02E-46E7-8E72-CCE6FC1A5A84Q38928302-AA1B98F3-46E6-4A34-9A97-DA56061E293BQ38959281-3DE071E6-BFB2-4A70-BBBD-616CD111540AQ38963389-E8A77350-565C-4D44-8A60-D530C81C6460Q39044774-DE677CD7-3D5F-4F4C-8ADA-D29C274EDF39Q41526373-3BA445EA-7DE1-4525-A9D9-AB405CF04E86Q42077295-F171138B-C85A-41FD-A82B-069C06A2296FQ42633014-F72AFB32-071C-46D0-8419-D99DEDE7F9D4Q47331810-20B75805-BE5C-4445-94F6-40F28B93FD2DQ47333263-6EDEE4A0-F4DF-442D-8BC0-654CEB4FF410Q47384439-41FF84B5-6821-4560-858D-29A5214B5FDEQ47403096-3939FD91-4E80-419C-82E0-67FEF74FC7DEQ47568807-76D9B7FB-743A-4580-9FB7-9AF386B5375FQ47724161-78B01823-D815-4566-AA90-99A0E8802E78Q47924035-804F422F-B281-4401-89F7-C395F8C7EEABQ48142540-35D143E1-9A8A-452D-A97F-54191666A010Q48524975-8C9C2268-A73F-4824-8BA6-1C67A6266CE6Q52312048-FBE8726F-9555-4E83-B97B-994D9C6D3AECQ54178337-A36F19BA-461B-4653-899E-839520AD372CQ55430578-7F01C923-C874-4E77-B682-80FADF77834AQ58750452-649A75B8-E43E-44C6-A9B8-A5DA849EB9C7
P2860
Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Recent Advances in Development ...... osity to Regulatory Acceptance
@ast
Recent Advances in Development ...... osity to Regulatory Acceptance
@en
Recent Advances in Development ...... osity to Regulatory Acceptance
@nl
type
label
Recent Advances in Development ...... osity to Regulatory Acceptance
@ast
Recent Advances in Development ...... osity to Regulatory Acceptance
@en
Recent Advances in Development ...... osity to Regulatory Acceptance
@nl
prefLabel
Recent Advances in Development ...... osity to Regulatory Acceptance
@ast
Recent Advances in Development ...... osity to Regulatory Acceptance
@en
Recent Advances in Development ...... osity to Regulatory Acceptance
@nl
P2860
P3181
P1476
Recent Advances in Development ...... osity to Regulatory Acceptance
@en
P2093
Masoud Jamei
P2860
P2888
P304
P3181
P356
10.1007/S40495-016-0059-9
P407
P577
2016-01-01T00:00:00Z
P6179
1038103764